Inflammation alters host physiology to promote cancer, as seen in colitis-associated colorectal
cancer (CRC). Here, we identify the intestinal microbiota as a target of inflammation that …

In vitro data suggest that a subgroup of NLR proteins, including NLRP12, inhibits the transcription
factor NF-κB, although physiologic and disease-relevant evidence is largely missing. …

The high prevalence of pre-existing immunity to adenovirus serotype 5 (Ad5) in human
populations may substantially limit the immunogenicity and clinical utility of recombinant Ad5 …

Enterobacteria, especially Escherichia coli, are abundant in patients with inflammatory bowel
disease or colorectal cancer (CRC). However, it is unclear whether cancer is promoted by …

Group 3 innate lymphoid cells (ILC3s) regulate immunity and inflammation, yet their role in
cancer remains elusive. Here, we identify that colorectal cancer (CRC) manifests with altered …

CATERPILLER (NOD, NBD-LRR) proteins are rapidly emerging as important mediators of
innate and adaptive immunity. Among these, Monarch-1 operates as a novel attenuating …

Maternal transmission and cage effects are powerful confounding factors in microbiome
studies. To assess the consequences of cage microenvironment on the mouse gut microbiome, …

Evidence supports involvement of microflora in the transition of chronic inflammation to
neoplasia. We investigated the protective efficacy of the probiotic VSL#3 in a model of colitis-…

Increasing evidence implicates the tumor microbiota as a factor that can influence cancer
progression. In patients with colorectal cancer (CRC), we found that pre-resection antibiotics …

Background Inflammatory bowel disease (IBD) therapies are modestly successful and
associated with significant side effects. Thus, the investigation of novel approaches to prevent …